Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ...

Drugmaker Novo Nordisk says it will make the popular weight GLP-1 weight loss medication Wegovy more affordable for those ...

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk ...

Wegovy-maker Novo Nordisk's CEO said on Monday a deal with the White House to slash prices on its popular weight‑loss drugs ...

Shares of LifeMD were higher after Novo Nordisk slashed prices for its GLP-1 obesity drugs for customers who pay out of pocket. The stock rose 5.8% to $4.90 in premarket trading. LifeMD said the lower ...

After [losing out to Pfizer]( ...

The drugmaker is holding a special shareholder meeting to vote on the appointment of a new board after the pharma giant lost ...

Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain ...

Novo Nordisk cuts obesity drug prices to compete with Eli Lilly, offering new patient deals and nationwide access.

Novo Nordisk A/S remains attractive with strong cash flow and robust pipeline. Click here to read why NVO stock is a Buy.

Novo Nordisk has started selling its weight-loss drug Wegovy for $349 a month to cash payers, implementing the price cut months earlier than planned under its agr ...

This prompted an unusual and bitter bidding war, where Doustdar goaded Pfizer to raise its bid during a press conference in the Oval Office. In the end, Pfizer won by matching Novo’s $10bn offer, as ...